mFast-SeqS-based aneuploidy score in circulating cell-free DNA is a prognostic biomarker in prostate cancer.
Sign Up to like & getrecommendations! Published in 2023 at "Molecular oncology"
DOI: 10.1002/1878-0261.13449
Abstract: Multiple prognostic biomarkers, including circulating tumor cell (CTC) counts, exist in metastatic castration-resistant prostate cancer (mCRPC) patients, but none of them have been implemented into daily clinical care. The modified fast aneuploidy screening test-sequencing system… read more here.
Keywords: dna; cell free; mcrpc patients; aneuploidy score ... See more keywords
The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population.
Sign Up to like & getrecommendations! Published in 2021 at "Prostate cancer and prostatic diseases"
DOI: 10.1038/s41391-021-00344-1
Abstract: BACKGROUND In 2004 docetaxel was the first life-prolonging drug (LPD) registered for metastatic castration-resistant prostate cancer (mCRPC) patients. Between 2011 and 2014 new LPDs for mCRPC (cabazitaxel, abiraterone, enzalutamide, and radium-223) were introduced in the… read more here.
Keywords: mcrpc; subgroup; mcrpc patients; prostate cancer ... See more keywords
Abstract 6698: Combinatorial genomic and epigenomic cell-free DNA analysis of high-risk metastatic castration resistant prostate cancer reveals prognostic liquid biopsy signatures
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-6698
Abstract: Background: Androgen receptor signaling inhibitors (ARSI) such abiraterone and enzalutamide have significantly improved clinical outcomes in metastatic castrate-resistant prostate cancer (mCRPC) patients. However, patients with genomic alterations in the androgen receptor (AR) and its enhancer… read more here.
Keywords: enhancer; cell free; mcrpc patients; high risk ... See more keywords
Baseline CTC subtype to predict outcomes on mCRPC patients (pts) receiving enzalutamide (E) compared to abiraterone (A).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.5070
Abstract: 5070Background: Prior response to A or E does not predict sensitivity to E following A or A following E. The detection of AR-V7 predicts insensitivity to either drug, but identifies only a portion ... read more here.
Keywords: mcrpc patients; outcomes mcrpc; ctc subtype; baseline ctc ... See more keywords
Early changes in PSA and association with outcomes in mCRPC patients.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.5063
Abstract: 5063Background: Declines in prostate specific antigen (PSA) levels at 12-weeks are currently used to evaluate treatments response in metastatic castration resistant prostate cancer (mCRPC). Early P... read more here.
Keywords: association outcomes; outcomes mcrpc; mcrpc patients; psa association ... See more keywords
cfDNA analysis of mCRPC patients expressing mutations in Wnt signaling.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.6_suppl.256
Abstract: 256Background: Alterations in Wnt signaling have been shown to play a role in the development of castrate resistant prostate cancer. Cell free DNA (cfDNA) isolated from patient plasma can provide a non-invasive way to further… read more here.
Keywords: wnt signaling; mcrpc patients; analysis mcrpc; cfdna analysis ... See more keywords
Combination of carboplatin (AUC4) and cabazitaxel (25 mg/m2) in mCRPC patients not or no longer responding to cabazitaxel monotherapy.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.6_suppl.371
Abstract: 371Background: Cabazitaxel monotherapy is a second line treatment option for mCRPC patients. However, not all patients have a PSA response on this treatment, while a proportion of patients develop resistance during cabazitaxel treatment. Platinum drugs… read more here.
Keywords: combination; mcrpc patients; cabazitaxel monotherapy; cabazitaxel ... See more keywords
Plasma-based exploratory biomarker analysis to evaluate GT0918 in a phase I/II study in mCRPC patients.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.7_suppl.279
Abstract: 279 Background: GT0918, a novel potent androgen receptor antagonist, has been evaluated in a ph 1/2 study in mCRPC patients for its safety and efficacy. Here using patient plasma samples, we explored cell-free DNA &… read more here.
Keywords: mcrpc patients; treatment; study mcrpc; gt0918 ... See more keywords
Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel – A Final Analysis of the Prosty II Trial
Sign Up to like & getrecommendations! Published in 2020 at "AntiCancer Research"
DOI: 10.21873/anticanres.14715
Abstract: Background/Aim: Our phase III trial showed that biweekly docetaxel (D) is better tolerated than triweekly D in metastatic castration-resistant prostate cancer (mCRPC). The safety of biweekly cabazitaxel (CBZ) post-docetaxel was studied in mCRPC. Patients and… read more here.
Keywords: cancer mcrpc; mcrpc patients; prostate cancer; metastatic castration ... See more keywords